Research Article
Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of α-galactosylceramide
Asako Chiba,
Shinji Oki,
Katsuichi Miyamoto,
Hiroshi Hashimoto,
Takashi Yamamura,
Sachiko Miyake,
Asako Chiba
National Institute of Neuroscience, NCNP and Juntendo University School of Medicine, Tokyo, Japan
Search for more papers by this authorShinji Oki
National Institute of Neuroscience, NCNP, Tokyo, Japan
Search for more papers by this authorKatsuichi Miyamoto
National Institute of Neuroscience, NCNP, Tokyo, Japan
Search for more papers by this authorHiroshi Hashimoto
Juntendo University School of Medicine, Tokyo, Japan
Search for more papers by this authorTakashi Yamamura
National Institute of Neuroscience, NCNP, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Sachiko Miyake
National Institute of Neuroscience, NCNP, Tokyo, Japan
Department of Immunology, National Institute of Neuroscience, NCNP, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8502, JapanSearch for more papers by this authorAsako Chiba,
Shinji Oki,
Katsuichi Miyamoto,
Hiroshi Hashimoto,
Takashi Yamamura,
Sachiko Miyake,
Asako Chiba
National Institute of Neuroscience, NCNP and Juntendo University School of Medicine, Tokyo, Japan
Search for more papers by this authorShinji Oki
National Institute of Neuroscience, NCNP, Tokyo, Japan
Search for more papers by this authorKatsuichi Miyamoto
National Institute of Neuroscience, NCNP, Tokyo, Japan
Search for more papers by this authorHiroshi Hashimoto
Juntendo University School of Medicine, Tokyo, Japan
Search for more papers by this authorTakashi Yamamura
National Institute of Neuroscience, NCNP, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Sachiko Miyake
National Institute of Neuroscience, NCNP, Tokyo, Japan
Department of Immunology, National Institute of Neuroscience, NCNP, 4-1-1 Ogawahigashi, Kodaira, Tokyo 187-8502, JapanSearch for more papers by this authorAbstract
Objective
OCH, a synthetic analog of α-galactosylceramide with a truncated sphingosine chain, stimulates natural killer T (NKT) cells to produce predominantly Th2 cytokines. Thus, OCH may be a potential agent for the treatment of Th1-mediated autoimmune diseases. This study was designed to evaluate the protective effects of OCH on collagen-induced arthritis (CIA) in mice.
Methods
Mice were immunized with type II collagen (CII) and injected intraperitoneally twice per week with OCH, before or after the onset of CIA. They were monitored to assess the effect of OCH treatment on the severity of disease. Anti-CII antibodies and cytokine production were measured by enzyme-linked immunosorbent assay. Expression of cytokine genes was determined by quantitative reverse transcriptase–polymerase chain reaction.
Results
OCH inhibited CIA in wild-type C57BL/6 (B6) mice but not in NKT-deficient mice. OCH suppressed CIA in SJL mice, which are prone to autoimmune diseases and have a deficiency in the number and function of NKT cells which is similar to that in patients with autoimmune diseases, even after disease has already developed. Disease protection conferred by OCH correlated with its ability to selectively induce Th2 cytokine production mediated by NKT cells and to promote collagen-specific Th2 responses. Neutralization of interleukin-4 (IL-4) or IL-10 with monoclonal antibodies abolished disease protection by OCH, indicating a critical role for these cytokines.
Conclusion
Taken together, our findings suggest that OCH holds possibilities as a therapeutic agent for autoimmune diseases such as rheumatoid arthritis.
REFERENCES
- 1 Van Roon JAG, Lafeber FPJG, Bijlsma JWJ. Synergistic activity of interleukin-4 and interleukin-10 in suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum 2001; 44: 3–12.
- 2 Walmsley M, Katsikis PD, Abney E, Parry S, Williams RO, Maini RN, et al. Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum 1996; 39: 495–503.
- 3 Joosten LAB, Lubberts E, Durez P, Helsen MMA, Jacobs MJM, Goldman M, et al. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997; 40: 249–60.
- 4 Horsfall AC, Butler DM, Marinova L, Warden PJ, Williams RO, Maini RN, et al. Suppression of collagen-induced arthritis by continuous administration of IL-4. J Immunol 1997; 159: 5687–96.
- 5 Apparailly F, Verwaerde C, Jacquet C, Auriault C, Sany J, Jorgensen C. Adenovirus-mediated transfer of viral IL-10 gene inhibits murine collagen-induced arthritis. J Immunol 1998; 160: 5213–20.
- 6 Ma Y, Thornton S, Duwel LE, Boivin GP, Giannini EH, Leiden JM, et al. Inhibition of collagen-induced arthritis in mice by viral IL-10 gene transfer. J Immunol 1998; 161: 1516–24.
- 7 Lubberts E, Joosten LAB, van den Bersselaar L, Helsen MMA, Bakker AC, van Meurs JBJ, et al. Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction. J Immunol 1999; 163: 4546–56.
- 8 Setoguchi K, Misaki Y, Araki Y, Fujio K, Kawahata K, Kitamura T, et al. Antigen-specific T cells transduced with IL-10 ameliorate experimentally induced arthritis without impairing the systemic immune response to the antigen. J Immunol 2000; 165: 5980–6.
- 9 Lubberts E, Joosten LAB, Chabaud M, van den Bersselaar L, Oppers B, Coenen-de Roo CJJ, et al. IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000; 105: 1697–710.
- 10 Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001; 166: 3499–505.
- 11 Morita Y, Yang J, Gupta R, Shimizu K, Shelden EA, Endres J, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001; 107: 1275–84.
- 12 Bendelac A, Rivera MN, Park SH, Roark JH. Mouse CD1-specific NK1 T cells: development, specificity, and function. Annu Rev Immunol 1997; 15: 535–62.
- 13 Hong S, Scherer DC, Singh N, Mendiratta SK, Serizawa I, Koezuka Y, et al. Lipid antigen presentation in the immune system: lessons learned from CD1d knockout mice. Immunol Rev 1999; 169: 31–44.
- 14 Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000; 21: 573–83.
- 15 Sumida T, Sakamoto A, Murata H, Makino Y, Takahashi H, Yoshida S, et al. Selective reduction of T cells bearing invariant Vα24JαQ antigen receptor in patients with systemic sclerosis. J Exp Med 1995; 182: 1163–8.
- 16 Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, et al. Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes. Nature 1998; 391: 177–81.
- 17 Illes Z, Kondo T, Newcombe J, Oka N, Tabira T, Yamamura T. Differential expression of NK T cell Vα24JαQ invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. J Immunol 2000; 164: 4375–81.
- 18 Kojo S, Adachi Y, Keino H, Taniguchi M, Sumida T. Dysfunction of T cell receptor AV24AJ18+,BV11+ double-negative regulatory natural killer T cells in autoimmune diseases. Arthritis Rheum 2001; 44: 1127–38.
- 19 Yoshimoto T, Bendelac A, Hu-Li J, Paul WE. Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin 4. Proc Natl Acad Sci U S A 1995; 92: 11931–4.
- 20 Mieza MA, Itoh T, Cui JQ, Makino Y, Kawano T, Tsuchida K, et al. Selective reduction of Vα14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol 1996; 156: 4035–40.
- 21 Gombert JM, Herbelin A, Tancrede-Bohin E, Dy M, Carnaud C, Bach J-F. Early quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. Eur J Immunol 1996; 26: 2989–98.
- 22 Hong SH, Wilson MT, Serizawa I, Wu L, Singh N, Naidenko OV, et al. The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7: 1052–6.
- 23 Singh AK, Wilson MT, Hong S, Olivares-Villagomez D, Du C, Stanic AK, et al. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J Exp Med 2001; 194: 1801–11.
- 24 Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K, et al. CD1d-restricted and TCR-mediated activation of Vα14. Nature 1998; 391: 177–81.
- 25 Brossay L, Chioda M, Burdin N, Koezuka Y, Casorati G, Dellabona P, et al. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med 1998; 188: 1521–8.
- 26 Spada FM, Koezuka Y Porcelli SA. CD1d-restricted recognition of syntheic glycolipid antigens by human natural killer T cells. J Exp Med 1998; 188: 1529–34.
- 27 Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing Th2 bias of natural killer T cells. Nature 2001; 413: 531–4.
- 28 Pal EA, Tabira T, Kawano T, Taniguchi M, Miyake S, Yamamura T. Costimulation-dependent modulation of experimental autoimmune encephalomyelitis by ligand stimulation of Vα14+ NK T cells. J Immunol 2001; 166: 662–8.
- 29 Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunization against heterologous type II collagen induces arthritis in mice. Nature 1980; 283: 666–8.
- 30 Campbell IK, Rich MJ, Bischof RJ, Dunn AR, Grail D, Hamilton JA. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol 1998; 161: 3639–44.
- 31
Campbell IK,
Hamilton JA,
Wicks IP.
Collagen-induced arthritis in C57BL/6 (H-2b) mice: new insights into an important disease model of rheumatoid arthritis.
Eur J Immunol
2000;
30:
1568–75.
10.1002/1521-4141(200006)30:6<1568::AID-IMMU1568>3.0.CO;2-R CAS PubMed Web of Science® Google Scholar
- 32 Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, et al. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278: 1623–6.
- 33 Sharif S, Arreaza GA, Zucker P, Mi Q-S, Sondhi J, Naidenko OV, et al. Activation of natural killer T cells by α-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat Med 2001; 7: 1057–62.
- 34 Mempel M, Ronet C, Suarez F, Gilleron M, Puzo, G, van Kaer L, et al. Natural killer T cells restricted by the monomorphic MHC class 1b CD1d1 molecules behave like inflammatory cells. J Immunol 2002; 168: 365–71.
- 35 Hammond KJL, Poulton LD, Palmisano LJ, Silveria PA, Godfrey DJ, Bazter AG. α/β-T cell receptor (TCR)+CD4-CD8-(NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 1998; 187: 1047–56.
- 36 Lehuen A, Lantz O, Beaudoin L, Laloux V, Carnaud C, Bendelac A, et al. Overexpression of natural killer T cells protects Vα14-Jα281 transgenic nonobese diabetic mice against diabetes. J Exp Med 1998; 188: 1831–9.
- 37 Wang B, Geng YB, Wang CR. CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes. J Exp Med 2001; 194: 313–9.
- 38 Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025–31.
- 39 Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907–16.
- 40 Brennan FM, Maini RN, Feldmann M. TNF alpha: a pivotal role in rheumatoid arthritis? Br J Rheumatol 1992; 31: 293–8.
- 41 Criscione LG, St Clair EW. Tumor necrosis factor-α antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol 2002; 14: 204–11.
- 42 Kong Y-Y, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304–9.
- 43 Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000; 43: 250–8.
- 44 Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay R, Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2523–30.
- 45 Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000; 43: 259–69.
